{"entity":{"id":"nct05171660","kind":"trial","name":"Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer","aka":[],"tldr":"A phase 3 trial of sintilimab, bevacizumab (glioblastoma use), fOLFOX (5-FU, leucovorin, oxaliplatin) and capecitabine in colorectal cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, active but no longer recruiting.","summary":"Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer is a phase 3, randomised interventional study registered as NCT05171660 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with a registry enrolment figure of 446 participants, started 2022-02-08 and due to reach its primary completion in 2026-12-30. Interventions recorded: Sintilimab; Bevacizumab; Oxaliplatin; Capecitabine. Conditions listed: Colorectal Cancer Stage IV. Primary outcome: Progression free survival time. Colorectal eligibility wording from the registry: \"Metastatic colorectal adenocarcinoma confirmed by histology, metastases cannot be removed\". Sites: China. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05171660","url":"https://clinicaltrials.gov/study/NCT05171660"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["sintilimab","bevacizumab-glioma","folfox","capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05171660","phase":"3","setting":"A Randomized, Open, Multicenter Phase III Clinical Trial of Combination of Sintilimab Injection (IBI308) and XELOX+Bevacizumab Compared With XELOX+Bevacizumab as 1st Line Therapy of RAS-Mutant Metastatic Colorectal Cancer","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","enrolled":446,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05171660/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}